NRX Pharmaceuticals Inc (NASDAQ:NRXP)’s traded shares stood at 0.42 million during the latest session, with the company’s beta value hitting 1.09. At the last check today, the stock’s price was $4.08, to imply a decrease of -9.22% or -$0.41 in intraday trading. The NRXP share’s 52-week high remains $7.33, putting it -79.66% down since that peak but still an impressive 73.04% since price per share fell to its 52-week low of $1.10. The company has a valuation of $49.29M, with an average of 4.81 million shares in intraday trading volume over the past 10 days and average of 1.03 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for NRX Pharmaceuticals Inc (NRXP), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give NRXP a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.29.
NRX Pharmaceuticals Inc (NASDAQ:NRXP) trade information
After registering a -9.22% downside in the latest session, NRX Pharmaceuticals Inc (NRXP) has traded red over the past five days. The 5-day price performance for the stock is 8.41%, and 239.67% over 30 days. With these gigs, the year-to-date price performance is 85.28%. Short interest in NRX Pharmaceuticals Inc (NASDAQ:NRXP) saw shorts transact 0.68 million shares and set a 4.8 days time to cover.
The extremes give us $2 and $2 for target low and target high price respectively. As such, NRXP has been trading 50.98% off suggested target high and 50.98% from its likely low.
NRX Pharmaceuticals Inc (NRXP) estimates and forecasts
Looking at statistics comparing NRX Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. NRX Pharmaceuticals Inc (NRXP) shares are 71.26% up over the last 6 months, with its year-to-date growth rate higher than industry average at 52.70% against 16.30%.
Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 5M.
NRXP Dividends
NRX Pharmaceuticals Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
NRX Pharmaceuticals Inc (NASDAQ:NRXP)’s Major holders
NRX Pharmaceuticals Inc insiders hold 23.56% of total outstanding shares, with institutional holders owning 6.05% of the shares at 7.92% float percentage. In total, 6.05% institutions holds shares in the company.
We also have AdvisorShares Trust-AdvisorShares Psychedelics ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the NRX Pharmaceuticals Inc (NRXP) shares. Going by data provided on Nov 30, 2024, AdvisorShares Trust-AdvisorShares Psychedelics ETF holds roughly 318.5 shares. This is just over 2.63% of the total shares, with a market valuation of $1.3 million. Data from the same date shows that the other fund manager holds a little less at 193.42, or 1.60% of the shares, all valued at about 0.79 million.
